Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: A double-blind randomized cross-over trial

Rheumatology

Volumn 49, Issue 12, 2010, Pages 2420-2428

  Shenoy, Padmanabha D ^a   Kumar, Sudeep ^a   Jha, Lalan K ^a   Choudhary, Sunil K ^a   Singh, Uttam ^a   Misra, Ramnath ^a   Agarwal, Vikas ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Endothelial dysfunction; Ischaemic ulcer; Phosphodiesterase inhibitors; Raynaud's phenomenon; Scleroderma; Tadalafil; Vasodilators

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ENALAPRIL; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; LOSARTAN; NIFEDIPINE; PENTOXIFYLLINE; PLACEBO; TADALAFIL;

ADD ON THERAPY; ADULT; ARTICLE; CENTRAL SEROUS RETINOPATHY; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; ENDOTHELIUM; FEMALE; FLOW MEDIATED DILATATION; FLUSHING; HUMAN; INSOMNIA; MALE; MIXED CONNECTIVE TISSUE DISEASE; MYALGIA; NASAL STUFFINESS; PATIENT ASSESSMENT; PRIAPISM; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RAYNAUD PHENOMENON; RHINORRHEA; SCLERODERMA; SIDE EFFECT; SKIN DEFECT; TREATMENT OUTCOME; ULCER; VERTIGO; VISUAL ANALOG SCALE;

ADULT; CARBOLINES; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; RAYNAUD DISEASE; SCLERODERMA, SYSTEMIC; TREATMENT OUTCOME; VASODILATOR AGENTS; YOUNG ADULT;

EID: 78549284312     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keq291     Document Type: Article

References (29)

1. Bowling JC, Dowd PM. Raynaud's disease. Lancet 2003; 361:2078-80.
2. Herrick A. Diagnosis and management of scleroderma peripheral vascular disease. Rheum Dis Clin North Am 2008;34:89-114.
3. Fries R, Shariat K, von Wilmowsky H, Böhm M. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation 2005;112:2980-5.
4. Campbell HE. Clinical monograph for drug formulary review: erectile dysfunction agents. J Manag Care Pharm 2005;11:151-71.
5. Baumhaekel M, Scheffler P, Boehm M. Use of tadalafil in a patient with a secondary Raynaud's phenomenon not responding to sildenafil. Microvasc Res 2005;69:178-9.
6. Aversa A, Vitale C, Volterrani M et al. Chronic administration of sildenafil improves markers of endothelial function in men with Type 2 diabetes. Diabet Med 2008; 25:37-44.
7. Rajagopalan S, Pfenninger D, Somers E et al. Effects of cilostazol in patients with Raynaud's syndrome. Am J Cardiol 2003;92:1310-5.
8. Sub-committee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
9. Black CM, Halkier-Sorensen L, Belch JJF et al. Oral iloprost in Raynaud's phenomenon secondary to systemic sclerosis. Br J Rheumatol 1998;37:952-60.
10. Steen VD, Medsger TA Jr. The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time. Arthritis Rheum 1997;40:1984-91.
11. Kahaleh B. Vascular disease in scleroderma: mechanisms of vascular injury. Rheum Dis Clin North Am 2008;34: 57-71.
12. Berkels R, Klotz T, Sticht G, Engelmann U, Klaus W. Modulation of human platelet aggregation by the phosphodiesterase type 5 inhibitor sildenafil. J Cardiovasc Pharmacol 2001;37:413-21.
13. McCullough AR. An update on the PDE-5 inhibitors (PDE-5i). J Androl 2003;24:S52-8.
14. Friedman EA, Harris PA, Wood AJJ, Stein CM, Kurnik D. The effects of tadalafil on cold-induced vasoconstriction in patients with Raynaud's phenomenon. Clin Pharmacol Ther 2007;81:503-9.
15. Schiopu E, Hsu VM, Impens AJ et al. Randomized placebo-controlled crossover trial of tadalafil in Raynaud's phenomenon secondary to systemic sclerosis. J Rheumatol 2009;36:2264-8.
16. Zusman RM, Prisant LM, Brown MJ. Effect of sildenafil citrate on blood pressure and heart rate in men with erectile dysfunction taking concomitant antihypertensive medication. Sildenafil Study Group. J Hypertens 2000;18: 1865-9.
17. Kloner RA, Brown M, Prisant LM, Collins M. Effect of sildenafil in patients with erectile dysfunction taking antihypertensive therapy. Sildenafil Study Group. Am J Hypertens 2001;14:70-3.
18. Ferri C, Valentini G, Cozzi F et al. for Systemic Sclerosis Study Group of the Italian Society of Rheumatology (SIR-GSSSc). Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine 2002;81:139-53.
19. Nihtyanova SI, Brough GM, Black CM, Denton CP. Clinical burden of digital vasculopathy in limited and diffuse cutaneous systemic sclerosis. Ann Rheum Dis 2008;67:120-3.
20. Wigley FM, Wise RA, Seibold JR et al. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. Ann Intern Med 1994;120:199-206.
21. Wigley FM, Seibold JR, Wise RA, McCloskey DA, Dole WP. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis. J Rheumatol 1992;19:1407-14.
22. Badesch DB, Tapson VF, McGoon MD et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000;132:425-34.
23. Korn JH, Mayes M, Matucci Cerinic M et al. Digital ulcers in systemic sclerosis: prevention by treatment with Bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004;50:3985-93.
24. Brueckner CS, Becker MO, Kroencke T et al. Effect of sildenafil on digital ulcers in systemic sclerosis - analysis from a single centre pilot study. Ann Rheum Dis 2010;69: 1475-8.
25. Soneja A, Drews M, Malinski T. Role of nitric oxide, nitroxidative and oxidative stress in wound healing. Pharmacol Rep 2005;57(Suppl.):108-19.
26. Isenberg JS, Ridnour LA, Espey MG, Wink DA, Roberts DD. Nitric oxide in wound-healing. Microsurgery 2005;25:442-51.
27. Milio G, Corrado E, Genova C. Iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis and the quality of life: a new therapeutic protocol. Rheumatology 2006;45:999-1004.
28. Sfikakis PP, Papamichael C, Stamatelopoulos KS et al. Improvement of vascular endothelial function using the oral endothelin receptor antagonist Bosentan in patients with systemic sclerosis. Arthritis Rheum 2007;56: 1985-93.
29. Herrick AL, Roberts C, Tracey A et al. Lack of agreement between rheumatologists in defining digital ulceration in systemic sclerosis. Arthritis Rheum 2009;60:878-82.